Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results

被引：8

作者：

Ogdie, Alexis ^{[1
,2
]}

Liu, Mei ^{[3
]}

Glynn, Meghan ^{[3
]}

Emeanuru, Kelechi ^{[3
]}

Harrold, Leslie R. ^{[4
]}

Richter, Sven ^{[5
]}

Guerette, Benoit ^{[5
]}

Mease, Philip J. ^{[6
,7
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA

[3] Corrona LLC, Waltham, MA USA

[4] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA

[5] Amgen Inc, Global Med Affairs, Thousand Oaks, CA 91320 USA

[6] Univ Washington, Sch Med, Div Rheumatol Clin Res, Swedish Med Ctr,Providence St Joseph Hlth, Seattle, WA USA

[7] Univ Washington, Sch Med, Div Rheumatol, Seattle, WA USA

来源：

JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 05期

关键词：

arthritis; methotrexate; psoriatic arthritis; TNF receptors; RECOMMENDATIONS; DISEASE; PSA;

D O I：

10.3899/jrheum.191209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA). Methods. Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included. Results. In total, 150 patients initiated rnonotherapy (aprernilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators. Conclusion. Findings suggest aprernilast monotherapy is an effective option for patients with oligoarticular PsA.

引用

页码：693 / 697

页数：5

共 50 条

[41] Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry
Ciurea, Adrian
Gotschi, Andrea
Kissling, Seraphina
Bernatschek, Alexander
Burki, Kristina
Exer, Pascale
Nissen, Michael J.
Moller, Burkhard
Scherer, Almut
Micheroli, Raphael
RMD OPEN, 2023, 9 (02):
[42] Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry
Mease, Philip J.
Etze, Carol J.
Huster, William J.
Muram, Talia M.
Armstrong, April W.
Lisse, Jeffrey R.
Rebello, Sabrina
Dodge, Rhiannon
Murage, Mwangi James
Greenberg, Jeffrey D.
Malatestinic, William N.
RMD OPEN, 2019, 5 (01):
[43] Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study
Fulvia Ceccarelli
Ramona Lucchetti
Carlo Perricone
Francesca Romana Spinelli
Enrica Cipriano
Simona Truglia
Francesca Miranda
Valeria Riccieri
Manuela Di Franco
Rossana Scrivo
Cristiano Alessandri
Guido Valesini
Fabrizio Conti
Clinical Rheumatology, 2019, 38 : 3145 - 3151
[44] Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting
Radi, Giulia
Campanati, Annamaria
Diotallevi, Federico
Molinelli, Elisa
Offidani, Anna
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2019, 154 (02): : 166 - 169
[45] Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Kavanaugh, Arthur
Mease, Philip J.
Gomez-Reino, Juan J.
Adebajo, Adewale O.
Wollenhaupt, Juergen
Gladman, Dafna D.
Hochfeld, Marla
Teng, Lichen L.
Schett, Georg
Lespessailles, Eric
Hall, Stephen
JOURNAL OF RHEUMATOLOGY, 2015, 42 (03) : 479 - 488
[46] Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease
Alexis Ogdie
John Tesser
Natalie J. Shiff
Iris Lin
Soumya D. Chakravarty
Michael Kelleman
Rhiannon Dodge
Robert R. McLean
Aaron Broadwell
Arthur Kavanaugh
Joseph F. Merola
Rheumatology and Therapy, 2023, 10 : 1479 - 1501
[47] Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA/SpA Registry
Mease, Philip J.
Etzel, Carol J.
Huster, William J.
Armstrong, April W.
Muram, Talia M.
Lisse, Jeffrey
Rebello, Sabrina
Dodge, Rhiannon
Murage, Mwangi J.
Greenberg, Jeffrey D.
Malatestinic, William N.
JOURNAL OF RHEUMATOLOGY, 2021, 48 (03) : 376 - 384
[48] Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
Strand, Vibeke
Mease, Philip J.
Maksabedian Hernandez, Ervant J.
Stolshek, Bradley S.
Liu, Lyrica X. H.
Collier, David H.
Kricorian, Gregory
Merola, Joseph F.
RMD OPEN, 2021, 7 (01):
[49] Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Mease, Philip J.
Chakravarty, Soumya D.
McLean, Robert R.
Blachley, Taylor
Kawashima, Toana
Lin, Iris
Kavanaugh, Arthur
Ogdie, Alexis
ACR OPEN RHEUMATOLOGY, 2022, 4 (05) : 447 - 456
[50] Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Manuel José Moreno-Ramos
Carlos Sanchez-Piedra
Olga Martínez-González
Carlos Rodríguez-Lozano
Carolina Pérez-Garcia
Mercedes Freire
Cristina Campos
Rafael Cáliz-Caliz
Jerusalem Calvo
Juan María Blanco-Madrigal
Ana Pérez-Gómez
María José Moreno-Martínez
Luis Linares
Fernando Sánchez-Alonso
Carlos Sastré
Isabel Castrejón
Rheumatology and Therapy, 2022, 9 : 1031 - 1047

← 1 2 3 4 5 →